Harvard Medical School, Johns Hopkins leaders join advisory board of AI startup

Listen
Text
  • Small
  • Medium
  • Large

Biotia, a startup combining next-generation DNA sequencing and artificial intelligence technology for precision detection and diagnosis of infectious disease, has raised $2.4 million in seed funding and expanded its scientific advisory board.

According to a Dec. 10 news release, new additions to the advisory board include Barry Zeman, a former hospital CEO and current chief strategy officer of health tech company Medsign; Don Goldmann, MD, clinical professor of pediatrics at Boston-based Harvard Medical School and professor of epidemiology, immunology and infectious diseases at Harvard T.H. Chan School of Public Health; and Steven Salzberg, PhD, a professor of biomedical engineering, computer science and biostatistics and the director of the Center for Computational Biology at Baltimore-based Johns Hopkins University.

The oversubscribed $2.4 million seed fundraise was led by biotech investment fund Falcon III Ventures. The funding will accelerate the development of Biotia's precision diagnostic software, which draws on the startup's massive collection of clinical data to compile a patient's complete microbial profile and predict drug resistance.

More articles on AI:
MemorialCare Innovation Fund joins $7M funding for nurse engagement AI platform
Harvard Law School researchers call for more regulation in medical AI
Google AI reads chest X-rays with 'expert-level accuracy'

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars